Cargando…

Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach

C-X-C motif chemokine receptor 4 (CXCR4) and somatostatin receptors (SSTR) are overexpressed in gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In this study, we aimed to elucidate the feasibility of non-invasive CXCR4 positron emission tomography/computed tomography (PET/CT) imaging in GE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Werner, Rudolf A., Weich, Alexander, Higuchi, Takahiro, Schmid, Jan S., Schirbel, Andreas, Lassmann, Michael, Wild, Vanessa, Rudelius, Martina, Kudlich, Theodor, Herrmann, Ken, Scheurlen, Michael, Buck, Andreas K., Kropf, Saskia, Wester, Hans-Jürgen, Lapa, Constantin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436508/ https://www.ncbi.nlm.nih.gov/pubmed/28529632 http://dx.doi.org/10.7150/thno.18754

Ejemplares similares

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [(68)Ga] Pentixafor Internalization in Neuroendocrine Tumor Cells
por: Weich, Alexander, et al.
Publicado: (2021)

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
por: Lapa, Constantin, et al.
Publicado: (2016)

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy
por: Werner, Rudolf A., et al.
Publicado: (2016)

CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas
por: Weich, Alexander, et al.
Publicado: (2021)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
por: Philipp-Abbrederis, Kathrin, et al.
Publicado: (2015)

Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography
por: Kosmala, Aleksander, et al.
Publicado: (2022)

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

Spectral Karyotyping and SNP Microarray Analysis Define Uniparental Disomy (UPD) as a Novel Mutational Mechanism in MSI- and CSI-Colorectal Cancers
por: Melcher, Ralph, et al.
Publicado: (2008)

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
por: Werner, Rudolf A., et al.
Publicado: (2018)

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4–Directed Molecular Imaging and Therapy
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
por: Buder, Kristina, et al.
Publicado: (2014)

Detection Rate of (68)Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy
por: Brumberg, Joachim, et al.
Publicado: (2020)

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers
por: Weich, Alexander, et al.
Publicado: (2022)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

(11)C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement
por: Lapa, Constantin, et al.
Publicado: (2016)

Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements
por: Chen, Xinyu, et al.
Publicado: (2020)

Moving into the next era of PET myocardial perfusion imaging: introduction of novel (18)F-labeled tracers
por: Werner, Rudolf A., et al.
Publicado: (2018)

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
por: Lapa, Constantin, et al.
Publicado: (2018)

Impact of (68)Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer
por: Serfling, Sebastian E., et al.
Publicado: (2023)

Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
por: Breun, Maria, et al.
Publicado: (2019)

Subcellular storage and release mode of the novel (18)F-labeled sympathetic nerve PET tracer LMI1195
por: Chen, Xinyu, et al.
Publicado: (2018)

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications
por: Werner, Rudolf A., et al.
Publicado: (2018)

(18)FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
por: Lapa, Constantin, et al.
Publicado: (2014)

Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
por: Bluemel, Christina, et al.
Publicado: (2016)

Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
por: Cytawa, Wojciech, et al.
Publicado: (2023)

CXCR4-directed theranostics in oncology and inflammation
por: Kircher, Malte, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hnigtfdl4vofv9gm73d9u715ov